Sustained hair regrowth with ritlecitinib to Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
March 2023
in “
SKIN The Journal of Cutaneous Medicine
”
TLDR Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
In the ALLEGRO phase 2b/3 study, a post hoc analysis revealed that the majority of patients with alopecia areata (AA) experienced sustained scalp hair regrowth through Week 48 after receiving ritlecitinib treatment, particularly those with a Severity of Alopecia Tool (SALT) score of ≤20 or ≤10 after Week 24. The safety profile of ritlecitinib up to Week 48 for SALT ≤20 responders was consistent with the overall study population. Serious adverse events included chemical poisoning and suicidal behavior in one patient in the 200/30 mg group and pulmonary embolism in one patient in the 50 mg group.
